Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 17/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 15/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8887373 | 0.99 | HTR2A (0.54) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL8887861 | 0.93 | HTR2A (0.57) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL8888110 | 0.92 | HTR2A (0.56) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| Ammonia Solution, Strong SCHEMBL906002 | 0.78 | HTR2C (0.64) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL8888435 | 0.78 | MTNR1A (0.43) | MTNR1AMTNR1B | |
| Fumaric Acid SCHEMBL4824846 | 0.77 | HTR2A (0.53) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL8888063 | 0.77 | HTR2C (0.65) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL25882779 | 0.76 | HTR2C (0.68) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL8888059 | 0.76 | HTR2A (0.61) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL7499133 | 0.75 | HTR2A (0.62) | HTR2AHTR2CHTR2BMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5633276-A | MELATONIN SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-05-27 | — | — | US | claimed |
| EP-0736028-A1 | INDOLINE DERIVATIVES, METHOD OF PREPARATION AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 1996-10-09 | — | — | EP | claimed |
| WO-1995017405-A1 | INDOLINE DERIVATIVES, METHOD OF PREPARATION AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 1995-06-29 | — | — | WO | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4502609-A2 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12201604-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240390327-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | JOHNS HOPKINS UNIVERSITY (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024155777-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4346810-A1 | COMPOSITIONS FOR REGULATING HOMEOSTASIS OF CORTISOL AND IMPROVING SLEEP QUALITY AND METHODS OF USE AND PRODUCTION THEREOF | Unigen, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| WO-2009053440-A1 | INDOLINE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050164987-A1 | Melatonin combination therapy for improving sleep quality | SEPRACOR INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-5633276-A | MELATONIN SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
| EP-0736028-A1 | INDOLINE DERIVATIVES, METHOD OF PREPARATION AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017405-A1 | INDOLINE DERIVATIVES, METHOD OF PREPARATION AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264521-A1 | Percutaneous absorption preparation | MTNR1A, MTNR1B, NPSR1 | HTR2A 108/4885HTR2C 277/4885HTR2B 150/4885 |
| US-12201604-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | HTR2A 39/4885HTR2C 69/4885HTR2B 63/4885 |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | HTR2A 39/4885HTR2C 69/4885HTR2B 63/4885 |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR2A 3098/4885HTR2C 2807/4885HTR2B 2477/4885 |
| US-20050164987-A1 | Melatonin combination therapy for improving sleep quality | MTNR1A, MTNR1B, CRY1 | HTR2A 11/4885HTR2C 31/4885HTR2B 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.